|
Market Cap (5-Jul) TBC |
Close (30-Jun) $0.059 |
Volume (30-Jun) 4,352,698 |
Shortsold (24-Jul) 256 (0.00%) (719th) |
|
52w High $0.000 |
52w Low $0.000 |
P/E - |
EPS - |
ANP released this announcement to the ASX on 13 July 2022, 9:24. The announcement is marked as price sensitive, and is 2 page(s) in length and 101.21kb in size.
You can view all announcements from ANP and see how they appear on a price chart on the announcements page.
At the date of this announcement, ANP was 0.003% short sold according to ASIC data. It was ranked the 655th most shorted stock on the ASX. It remains ranked 719th as of the latest reported data (24 July 2023).
| Other Recent Announcements from ANP | |
|---|---|
| MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK | 27 June 2023, 15:46 |
| First Patient Dosed in ATL1102 Phase IIb DMD Trial | 8 June 2023, 8:38 |
| Shareholder Newsletter | 6 June 2023, 15:47 |
| ATL1102 DMD Clinical Trial Application Submitted in Europe | 13 July 2022, 9:24 |
| Proteomics and disease marker identification in DMD Webinar | 28 June 2022, 16:57 |
| ANP to Present at the PPMD Annual Conference 2022 | 24 June 2022, 9:30 |
| New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2 | 20 June 2022, 9:34 |
You must be logged in to post a reply.
Antisense Therapeutics 